ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

<p>CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/contrafect-announces-fda-clearance-of-cf-370-ind-application-to-proceed-with-phase-1-clinical-study/">ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>